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Introduction
One of the amazing features of the corpus luteum (CL) is
the rapidity with which a very heterogeneous population
of cells becomes organized into a functional unit. These
diverse cells then communicate both directly and through
paracrine mediators to facilitate the steroidogenic func-
tion and also the transient nature of the CL. Once the hor-
monal regulators of luteal function and demise (for
example, LH and prostaglandin F2α) had been clearly
delineated, considerable effort in the late 1970s and
1980s was spent characterizing the morphological and
functional characteristics of the large and small steroidog-
enic cells. This was followed in the 1990s by increased
interest in the roles that nonsteroidogenic cells, including
endothelial cells, fibroblasts, pericytes and immune cells,
might have in luteal function. It is now thought that the
nonsteroidogenic cells are very active participants in regu-
lating the functional capacity and lifespan of the CL. These
cells communicate with the steroidogenic cells through
the paracrine signaling molecules that they produce, and
also through direct cell contacts. One form of direct cell-
cell signaling that may serve to activate resident immune
cells is major histocompatibility complex (MHC) mole-
cule-dependent interaction between luteal cells with T
lymphocytes. Expression of MHC molecules, and recogni-
tion of antigenic peptides presented in the context of
MHC molecules, serves as a means to regulate the activa-
tion of T lymphocytes, thus controlling cytokine produc-
tion and/or cytolysis.
Expression of MHC Molecules by Luteal Cells
Like the majority of other somatic cell types, luteal cells
express class I MHC molecules. What is surprising is that
luteal cells of several species, including the cow, also
express class II MHC molecules [1-5]. However, the iden-
tity of cells expressing class II MHC in the CL is somewhat
in question. Class II MHC expression is typically limited
to cells of the immune system that are regarded as "profes-
sional" antigen presenting cells, such as macrophages,
dendritic cells, and to a lesser extent, B cells. Macrophages
present within the CL would therefore certainly account
for a percentage of the class II-positive cells. However,
flow cytometric studies of dispersed bovine and ovine
luteal cells demonstrated the presence of class II MHC
molecules on both large and small cell populations [1,2],
suggesting that, in addition to luteal macrophages (which
would be included in the small cell fraction), the ster-
oidogenic luteal cells also express class II MHC. Further,
the bovine large luteal cell population was subdivided
into two groups, large dense cells and large less-dense cells
[1]. Both populations contain class II MHC-positive cells,
but the large less-dense population contained the highest
percentage of class II MHC-positive cells. The identity of
the cells comprising these two populations is not known,
but it is possible that one population represents the large
steroidogenic cells, and the other population is composed
of aggregates of luteal endothelial cells. A subpopulation
of luteal endothelial cells expressing class II MHC has
recently been identified [6].
In the human, luteinization induces the expression of
class II MHC molecules on granulosal cells [7], and
expression of both class I and class II MHC molecules
increases on granulosal cells in the late luteal phase [3]. In
contrast, minimal class II MHC expression is detected in
developing bovine CL [1]. Class II MHC expression is
Published: 10 November 2003
Reproductive Biology and Endocrinology 2003, 1:93
Received: 14 April 2003
Accepted: 10 November 2003
This article is available from: http://www.rbej.com/content/1/1/93
© 2003 Cannon and Pate; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in 
all media for any purpose, provided this notice is preserved along with the article's original URL.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/93
Page 2 of 7
(page number not for citation purposes)
elevated in the bovine CL by midcycle, and in bovine and
ovine CL, class II MHC expression is higher near the time
of luteal regression compared with midcycle [1,2,5]. In
contrast to the bovine and ovine CL, class II MHC expres-
sion in the equine CL is not elevated until after the decline
in circulating progesterone concentrations associated with
initiation of luteal regression [4]. Significantly, in each of
these species, expression of class II MHC is substantially
less in CL from pregnant animals compared with non-
pregnant animals [1,2,4]. In the chicken, cells expressing
class II MHC have been identified in the theca layer of
normally growing and pre-ovulatory follicles [8,9]. The
percentage of cells expressing class II MHC was greater in
post-ovulatory follicles and atretic follicles compared with
pre-ovulatory follicles, and class II MHC-positive cells are
found in both the thecal and granulosal layers of post-
ovulatory and atretic follicles [9].
Given the information available describing the expression
pattern of class II MHC molecules in the CL, a role for
class II MHC molecules in the process of luteal regression
has been proposed. The increase in expression of class II
MHC molecules between early and midcycle CL [1] coin-
cides with the acquisition of luteolytic capacity. Expres-
sion of class II MHC molecules on the surface of luteal
cells increases near the time of natural luteal regression
and when luteal regression is induced by PGF2α [1,5] but
is lower in pregnant compared to non-pregnant animals
[1,2,4]. From this observation it can be inferred that class
II MHC expression must be attenuated as part of the
mechanism that inhibits luteal regression during mater-
nal recognition of pregnancy. In addition, bovine luteal
cells stimulate T lymphocyte proliferation in vitro, and
they are more potent stimulators of proliferation when
derived from CL collected after administration of PGF2α to
the cow [10]. This indicates that there is a change in the
character of luteal cells that enhances their ability to stim-
ulate the activation of T lymphocytes.
A physiological role for MHC molecules in luteal function
is supported by the observation that both class I and class
II molecules are expressed by luteal cells in vivo, and the
expression of class II molecules varies with functional
state of the CL. These observations have given rise to the
hypothesis that the demise of the corpus luteum may
involve local autoimmune-response mechanisms facili-
tated by increased expression of cell surface class II MHC
at the time of luteal regression.
Major Histocompatibility Complex Molecules, 
Antigen Processing, and Autoimmunity
Stimulation of T lymphocyte activation is dependent on
the specific interaction of a T cell receptor for antigen
(TCR) on the T cell with MHC molecules located on the
surface of the target cell [11]. The outcome of binding of
the TCR to the MHC molecule is determined by the pep-
tides bound to the MHC molecules. In the context of T cell
responsiveness to a given cell or tissue, changes in the
array of MHC-bound peptides presented to T lymphocytes
can determine whether T cells are activated by the MHC
molecules in a given tissue, or alternatively, whether T
cells will remain in an unactivated state, a condition
known as immunological tolerance.
Antigenic peptides that are presented to T cells via MHC
molecules are derived from proteins that are proteolyti-
cally digested into short peptides prior to binding to MHC
molecules. Collectively, the proteolytic degradation of
antigenic proteins and the binding of the resulting short
peptides to MHC molecules is called antigen processing.
Since antigen processing can determine the types of pep-
tides bound to MHC molecules, this process can impact
whether cells within a tissue are able to activate T lym-
phocytes, thereby stimulating an immune response.
Class I MHC
Processing of peptides for presentation in the context of
class I MHC molecules is carried out by the proteasome.
The proteasome is a cytosolic protease complex composed
of multiple subunits that is responsible for the majority of
intracellular protein turnover, and also generates peptides
that are presented to T cells via class I MHC molecules
(Figure 1; [12]). The catalytic core of the proteasome,
referred to as the 20S proteasome, is composed of two het-
erologous families of subunits, termed α and β subunits.
The proteasome β subunits contain the active proteolytic
sites [13]. The composition of the 20S proteasome is bal-
anced between expression of constitutive β subunits
under normal conditions, and expression of IFN-γ-induc-
ible subunits during inflammatory conditions. Interferon-
γ induces the replacement of constitutively expressed β-
subunits with alternative β-subunits involved in antigen
processing [14-18]. The genes encoding two of these IFN-
γ-induced subunits, LMP2 and LMP7, are located within
the class II MHC gene region [19-21] and these subunits
have limited homology to the constitutive subunits Y and
X, respectively [14,22]. The third IFN-γ-inducible subunit,
originally termed MECL-1 and also referred to as LMP10
[17], is similarly homologous to the constitutive β-subu-
nit Z [23]. Thus, replacement of the constitutive β-subu-
nits X, Y and Z with the IFN-γ-inducible subunits (LMP7,
2 and 10) alters the peptide cleavage patterns of the pro-
teasome [24,25], resulting in alterations in the repertoire
of antigenic peptides presented by class I MHC molecules.
Interestingly, the IFN-γ-inducible subunits and their con-
stitutive homologues seem to be reciprocally regulated.
Tissues expressing high levels of LMP2, LMP7, or LMP10
were observed to have low levels of the constitutive
homologous subunits [26]. Also, IFN-γ coordinately
induces expression of LMP2, LMP7 and LMP10 withReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/93
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concurrent reduction in expression of the constitutive
homologues [17].
The most notable instance in which IFN-γ-inducible pro-
teasome subunits are suspected to play a role in induction
of an autoimmune response is autoimmune thyroiditis.
The thyrocytes themselves appear to act as antigen pre-
senting cells during the progression of the disease, stimu-
lating the activation of T lymphocytes [27]. Studies of
patients with Grave's disease and Hashimoto's thyroiditis,
both of which are autoimmune thyroid disorders, found
very high expression of LMP2 and LMP7 in the thyrocytes
themselves [28]. This implies that proteasomes in these
cells generate peptides that, when bound to class I MHC
molecules, stimulate the activation of CD8+ cytotoxic T
lymphocytes, which infiltrate the thyroid tissue in massive
numbers and exert cytotoxic effects on the thyrocytes [29].
We have recently demonstrated that interferon-γ-induci-
ble subunits of the proteasome (mRNAs and protein) are
expressed within the bovine corpus luteum [30]. Since
bovine luteal cells isolated from regressing CL more
potently stimulate T lymphocyte proliferation compared
to luteal cells from midcycle CL [10], we hypothesized
Schematic representation depicting processing of antigens presented by class I MHC molecules Figure 1
Schematic representation depicting processing of antigens presented by class I MHC molecules. 1) Intracellular 
proteins are proteolytically degraded within proteasomes. 2) Proteolytic degradation of intracellular proteins yields antigenic 
peptides of nine to eleven amino acids. 3) Antigenic peptides generated by the proteasomes are transported into the endoplas-
mic reticulum. 4) Newly synthesized class I MHC molecules bind antigenic peptides within in the endoplasmic reticulum. 5) 
Class I MHC-antigenic peptide complexes are exported through the Golgi and to the cell surface, for presentation of antigenic 
peptide to CD8+ T cells.
Proteasome
Antigenic
Peptides
1
2
3
4
5
Endoplasmic
Reticulum
Secretory
VesicleReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/93
Page 4 of 7
(page number not for citation purposes)
that IFN-γ-inducible proteasome subunits would be
upregulated in luteal tissue near the time of luteal
regression. Such a change in proteasome subunit expres-
sion could induce alterations in the array of self-peptides
presented to T cells in the context of class I MHC mole-
cules during luteal regression, which could explain the
enhancement in the ability of luteal cells to stimulate T
cell activation following PGF2α administration. However,
we discovered that LMP7 and LMP10 were expressed in
the CL at all stages of the estrous cycle, with no upregula-
tion following induction of luteal regression with PGF2α.
No changes were observed in LMP7 expression through-
out the estrous cycle, but LMP10 expression was less in
early CL, and greater in midcycle and late CL [30].
Class II MHC
Class II MHC molecules, typically expressed on antigen
presenting cells of the immune system (ie. macrophages,
dendritic cells and B lymphocytes), bind short peptides
derived from intracellularly processed proteins [31]. Class
II MHC molecules are heterodimeric proteins composed
of non-covalently associated α and β chains. Assembly of
the class II MHC complex occurs within the endoplasmic
reticulum (ER), and involves not only α and β chains, but
a third, non-polymorphic glycoprotein called the invari-
ant chain (Ii). As class II MHC molecules are synthesized,
they immediately bind to Ii, a portion of which occupies
the peptide binding groove of the MHC molecule [32].
Invariant chain serves a dual function, directing intracel-
lular transport of class II MHC molecules [33,34] and
ensuring that binding of "inappropriate" peptides does
not occur prematurely [32]. The MHC class II-Ii complex
is then transported into endosomes, in which proteolysis
by cathepsins and lysozomal proteases degrade the Ii into
a peptide called class II-associated invariant chain peptide
(CLIP; [35,36]). Prior to binding of antigenic peptides by
class II MHC molecules, the CLIP fragment bound to the
peptide binding groove must be removed. A class II MHC-
like heterodimeric protein generically referred to as DM
co-localizes with class II MHC molecules in endosomal
compartments [37] and catalyzes the removal of CLIP
from the peptide binding groove of the class II MHC mol-
ecule [38,39]. Following CLIP removal, the class II MHC
molecule is free to bind processed antigen, before trans-
port to the cell surface (Figure 2). The ability to process
and present antigen in a manner dependent on class II
MHC can be conferred to non-antigen presenting cells by
transfection with a class II MHC molecule, Ii, and DM.
These appear to be minimal yet sufficient components
required for reconstitution of the antigen processing
machinery [40].
Numerous autoimmune diseases are associated with aber-
rant expression of class II MHC molecules, including insu-
lin-dependent diabetes mellitus and autoimmune
thyroiditis, which are endocrine autoimmune disorders.
In these diseases, the target cells express Ii and DM mole-
cules, indicating that they are acting as antigen presenting
cells capable of stimulating activation of CD4+ T cells.
Both Ii and DM mRNAs are expressed within bovine luteal
tissue, with DMα and DMβ being elevated in midcycle
compared to early CL [41], and bovine luteal cells are
potent stimulators of class II-MHC dependent T cell pro-
liferation [10]. Therefore, cells within the CL are able to
process and present antigens to T cells in the context of
class II MHC, which may predispose luteal cells to an
autoimmune-type MHC-mediated response during luteal
regression.
The local inflammation that occurs concurrently with
autoimmune diseases is often attributed to pro-inflamma-
tory cytokines produced by Th1 cells. The mRNAs for sev-
eral pro-inflammatory T cell-derived cytokines, and in
some cases the proteins themselves, are present in the CL
[5,42-46]. The presence of T cell-derived cytokines in
luteal tissue suggests that the T lymphocytes present
within the tissue are activated. Activated T lymphocytes
produce IFN-γ and TNF-α, which increase expression of
class I and class II MHC molecules on luteal cells, as well
as inhibit progesterone production [47,48]. Thus, a posi-
tive feedback loop of antigenic peptide presentation and T
cell activation could occur to facilitate the rapid demise of
the tissue that occurs during luteolysis.
The Role of Costimulation In T Cell Activation
The presence of class I and class II MHC molecules on the
surface of a cell allows the cell to interact with CD8+ and
CD4+ T lymphocytes, respectively. However, there are two
possible outcomes of MHC-mediated cellular interactions
with T cells. In one instance, binding of MHC molecules
to the TCR can occur in the absence of accompanying
interactions between additional cell surface molecules. In
this case an inactive state known as anergy will be induced
in the T cells [49,50]. Induction of anergy is one means by
which tolerance to antigens in peripheral tissues is
induced, thus avoiding an autoimmune response [51].
Anergic T cells are prevented from carrying out their effec-
tor functions (cytokine secretion in the case of CD4+ T
cells; cytotoxic activity in the case of CD8+ cells).
Alternatively, MHC-TCR ligation can occur in conjunction
with a second interaction known as costimulation. Cos-
timulatory signals are delivered to T cells by the cell sur-
face proteins B7-1 and/or B7-2, also known as CD80 and
CD86, respectively [52-54]. These ligands, when present
on the antigen presenting cell surface, bind to the CD28
cell surface molecule on T cells and provide the costimu-
latory signal that promotes T cell survival [55] and
induces T cell activation and clonal expansion [49,52,56],
allowing the T cell to carry out its effector functions.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/93
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Therefore, while generation of sets of self-derived peptides
capable of binding to MHC molecules and stimulating the
activation of self-reactive T cells may predispose cells and
tissues to an autoimmune response, the absence of a cos-
timulatory signal can result in induction of tolerance to a
tissue or cell type rather than activation of lymphocytes
and induction of an immune response [57].
We recently demonstrated the expression of CD80 and
CD86 in bovine luteal tissue. Similar to the pattern of
DMα and DMβ expression, steady-state concentrations of
CD80 and CD86 mRNA were greater in the bovine CL
during midcycle as compared with early CL [58]. In func-
tional studies, antibodies against CD80 or CD86 inhib-
ited luteal cell-stimulated proliferation of T cells. These
data indicate that bovine luteal cells express functional
costimulatory molecules, which enable them to provide
the costimulatory signal necessary for activation of T cells.
Conclusions
From the observation that expression of MHC molecules
changes with functional state of the CL, it may be inferred
Schematic representation depicting processing of antigens presented by class II MHC molecules Figure 2
Schematic representation depicting processing of antigens presented by class II MHC molecules. 1) Extracellular 
and integral membrane proteins are internalized into endosomes via endocytosis. 2) Lysozomes fuse with endosomes. 3) Pro-
teolytic degradation of endocytosed proteins occurs in the endolysozomal vesicle, resulting in the generation of antigenic pep-
tides. 4) A specialized subcellualr organelle containing the class II MHC molecules, invariant chain, and DM fuses with the 
endolysozomal vesicle. This results in proteolytic degradation of invariant chain to CLIP. DM then catalyzes removal of clip, and 
the empty class II MHC molecules then bind antigenic peptides. 5) Class II MHC-antigenic peptide complexes are then 
exported to the cell surface, for presentation of antigenic peptide to CD4+ T cells.
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that these glycoproteins have a role in luteal physiology.
Since class II MHC molecules increase during luteolysis
and are suppressed during maternal recognition of preg-
nancy, it is likely that they are involved in luteal regres-
sion. Presentation of peptides in the context of MHC
molecules would result in activation of T lymphocytes,
with subsequent release of pro-inflammatory cytokines
and cytolysis. Luteal tissue contains the intracellular pro-
teins that are necessary for processing and presentation of
antigenic peptides (LMP 7, LMP 10, Ii, DM), and the cell
surface molecules necessary for costimulation (CD80,
CD86) are also expressed. Further, these components are
all apparently quite functional, since luteal cells are
potent stimulators of T cell proliferation. Collectively,
these events closely resemble those that occur in tissues
undergoing autoimmune responses. Thus, we propose
that the progression of luteolysis involves a localized
autoimmune response involving MHC-mediated antigen
presentation to T lymphocytes. The exact identity of the
antigen-presenting cells is yet to be determined. Finally, it
must also be recognized that the role of MHC molecules
on luteal cells may be something other than to promote
luteal regression. An alternative hypothesis is that MHC
molecules are present in the CL to promote tolerance, par-
ticularly in the event of pregnancy. Clearly, the story of
MHC molecules in the CL is just beginning to unfold.
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